<DOC>
	<DOCNO>NCT00401323</DOCNO>
	<brief_summary>The purpose study compare time progression overall survival treatment Taxotere plus cisplatin versus cisplatin plus 5-FU ( PF treatment group ) first line treatment patient recurrent and/or metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>Taxotere ( Docetaxel ) 1st Line Treatment Recurrent/Metastatic Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasm Recurrence , Local</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients histologically cytologically document squamous cell carcinoma head neck ( SCCHN ) ( eligible primary site : oral cavity , oropharynx , hypopharyx , larynx ) present locally recurrent and/or metastatic disease , least 1 unidimensionally bidimensionally measurable lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>